Editing
Landmark studies
(section)
Jump to navigation
Jump to search
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
==== Castrate-Resistant Prostate Cancer ==== ===== Non-metastatic ===== * ARAMIS NEJM 2018 (darolutamide) * SPARTAN NEJM 2018 (apalutamide) * PROSPER NEJM 2018 (enzalutamide) ===== Metastatic ===== Pre-docetaxel * AFFIRM NEJM 2012 (enzalutamide) * PREVAIL NEJM 2014 (enzalutamide) * COU-AA-302 * TAX-327 * IMPACT Post-docetaxel * COU-AA-301 * VISION (177Lu-PSMA-617) * PROfound NEJM 2020 (Olaparib) * Denosumab vs. zoledronate * TheraP (177Lu-PSMA-617 vs. cabazitaxel) * ALSYMPCA (Radium-223) Incidence of germline mutations in genes mediating DNA-repair processes in prostate cancer NEJM 2016
Summary:
Please note that all contributions to UrologySchool.com may be edited, altered, or removed by other contributors. If you do not want your writing to be edited mercilessly, then do not submit it here.
You are also promising us that you wrote this yourself, or copied it from a public domain or similar free resource (see
UrologySchool.com:Copyrights
for details).
Do not submit copyrighted work without permission!
Cancel
Editing help
(opens in new window)
Navigation menu
Personal tools
Not logged in
Talk
Contributions
Create account
Log in
Namespaces
Page
Discussion
English
Views
Read
Edit
Edit source
View history
More
Search
Navigation
Main page
Clinical Tools
Guidelines
Chapters
Landmark Studies
Videos
Contribute
For Patients & Families
MediaWiki
Recent changes
Random page
Help about MediaWiki
Tools
What links here
Related changes
Special pages
Page information